Prof. Stephen Caddick, UCL Vice-Provost (Enterprise) and Vernon Professor of Organic Chemistry and Chemical Biology, Department of Chemistry, UCL 

Stephen is a co-founder of ThioLogics. He fronts an internationally leading interdisciplinary research group at UCL (click here). He has authored  more than 150 peer-review publications and has made significant contributions in organic synthesis, catalysis, chemical biology and medicinal chemistry areas. He is a former Head of the Department of Chemistry at UCL and  is currently Vice-Provost (Enterprise) responsible for leading and developing UCL’s Enterprise Strategy, promoting entrepreneurship, promoting academic-business collaboration and partnership and maximising revenue from the commercialisation of research technology. Prof. Caddick has many external appointments. He is currently a member of the board of UCL Business, the Greater London Assembly’s London Enterprise Panel (LEP) and the Scientific Advisory Board of MRC Technology. He is chair of the LERU Enterprise and Innovation Community (EIC) and has been a member of a variety of research council’s funding committees and consultant for many pharmaceutical companies and chemical companies.

Dr James Baker, Lecturer in Chemical Biology, Department of Chemistry, UCL

James is a co-founder of ThioLogics. He is a lecturer in Chemical Biology at the Department of Chemistry, UCL (click here).  His research interests lie in the areas of chemical biology, organic synthesis and medicinal chemistry, and he has over 20 peer reviewed articles and patent applications.  He fronts a research group that carries out highly interdisciplinary and collaborative research, with a focus in the area of bioconjugation.  The group aims to develop innovative methodologies to carrying out protein modification, enabling new approaches to the study of biological systems and the discovery of promising novel therapeutic entities.  James carried out his MSci in Chemistry at the University of Nottingham in 2000.  He then worked at Novartis as a medicinal chemist for a short period before carrying out his PhD in Bristol in synthetic organic chemistry.  He then moved to UCL in 2005 as a postdoctoral researcher before commencing his RCUK fellowship in Jan 2007.

Prof. Kerry Chester, Team Leader: Antibody Based Medicines, UCL Cancer Institute

Kerry leads the Antibody Therapeutics Group at the UCL Cancer Institute (click here). Her main research interests are design and construction of antibody-based medicines and the interaction of these agents with specific cancer targets. The work is largely translational and aimed at developing new treatments for clinical use. To facilitate this, her group has established an academic GMP facility to make clinical grade recombinant proteins for use in Phase I/II cancer trials. Kerry’s current research includes developing antibodies as cancer imaging agents, as therapeutic fusion proteins and to target nanomedicines.

Felix Schumacher, Department of Chemistry, UCL

Felix Schumacher is a co-founder of Thiologics. He is currently conducting his doctorate with Dr James Baker at UCL, funded by the Wellcome Trust. Felix is holds a BSc and a MSc in biochemistry which he obtained at the Technische Universität München (Germany) in the group of Prof Johannes Buchner and Dr Gisela Keller (University Hospital Rechts der Isar). During his undergraduate studies he has visited the lab of Prof Lloyd Ruddock (Oulu/ Finland) to carry out research on an industry-related project. Felix has won numerous prizes at national and international conferences for his work on Next Generation Maleimide-based bioconjugation.